


Details:
Ulotaront (SEP-363856), a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia as well as the adjunctive treatment of MDD, with additional indications under consideration.
Lead Product(s): Ulotaront
Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Under the partnership to develop NFL-101, the company’s drug candidate Tobacco leaf protein for smoking cessation, for the Indian market with Themis Medicare Ltd., will purchase Active Pharmaceutical Ingredient (API) from NFL Biosciences.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Artemis Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 05, 2022
Details:
NFL-101 (tobacco leaf protein), is a natural product based on a standardized extract of tobacco leaf patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
The poster highlights data from preclinical studies showing that NYX-783, an NMDA receptor positive allosteric modulator, builds long-lasting fear-inhibitory memories in PTSD-relevant models, ultimately leading to reduced spontaneous recovery of fear.
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
NYX-783, an NMDA receptor positive allosteric modulator, demonstrates an ability to build long-lasting fear-inhibitory memories in PTSD-relevant models, ultimately leading to a stabilization of fear extinction.
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
NYX-783, a novel NMDA receptor positive allosteric modulator signicantly reduced spontaneous recovery of fear in mice in the conventional auditory fear-conditioning model. NYX-783 also reduced spontaneous recovery in the single-prolonged stress model of PTSD.
Lead Product(s): NYX-783
Therapeutic Area: Psychiatry/Psychology Product Name: NYX-783
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
NRCT-101SR significantly reduced ADHD core symptoms. Safety data collected from more than 200 individuals in multiple studies revealed that NRCT-101SR is well tolerated with an overall strong safety profile and fewer adverse events compared to placebo.
Lead Product(s): Magnesium L-Threonate
Therapeutic Area: Psychiatry/Psychology Product Name: NRCT-101SR
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Proceeds from the offering to be used to advance PRAX-114 into and through the completion of the Phase 2/3 Aria Study in monotherapy major depressive disorder, which is intended to satisfy one of two registrational trials required by the USFDA.
Lead Product(s): PRAX-114
Therapeutic Area: Psychiatry/Psychology Product Name: PRAX-114
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $91.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 13, 2021
Details:
Troriluzole 200 mg administered once daily as adjunctive therapy in OCD patients with inadequate response to standard of care treatment showed consistent numerical improvement over placebo on the Yale-Brown Obsessive Compulsive Scale at all study timepoints.
Lead Product(s): Troriluzole
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
Nobilis Therapeutics has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with panic disorder (PD).
Lead Product(s): Xenon,Oxygen,Nitrogen
Therapeutic Area: Psychiatry/Psychology Product Name: NBTX-001
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020